STIM

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 27, 2024
Quality of life, Indian stock exchange, Patient, Employment, Compensated emancipation, STIM, Marketing, RSU, Pharmaceutical industry

MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees.

Key Points: 
  • MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees.
  • In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
  • Each of the RSU grants vests ratably in equal installments on the first, second, third and fourth anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date.
  • The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

Retrieved on: 
Monday, March 25, 2024
Depression, Prevalence, Data analysis, MDD, COVID-19, Patient, Education, Ageing, Transcranial magnetic stimulation, TMS, DSM-IV codes, Quality of life, Adolescence, Safety, Marketing, STIM, FDA, Parent, Food, Pharmaceutical industry

NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.

Key Points: 
  • NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.
  • "The prevalence of depression in adolescents and young adults has been accelerating since the COVID-19 pandemic.
  • "NeuroStar’s TMS therapy now offers a promising first-line treatment for adolescents, backed by real-world data and impressive response rates consistent with response rates for adults.
  • This advancement has the potential to set a new treatment paradigm for how we address depression in our youth."

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

Retrieved on: 
Thursday, March 7, 2024
TMS, Mental health, TCN, Transcranial magnetic stimulation, TRD, Marketing, FDA, Quality of life, Hope, Standard of care, STIM, Depression, Patient, DSM-IV codes, Mental, MDD, Partnership

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers.

Key Points: 
  • MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers.
  • Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.
  • "Transformations Care Network's alliance with NeuroStar is more than a milestone; it is a tangible manifestation of our vision to integrate the most advanced treatments in our suite of services," said Brian Wheelan, Chief Executive Officer at Transformations Care Network.
  • To learn more about Transformations Care Network, visit www.transformationsnetwork.com .

Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call

Retrieved on: 
Tuesday, February 20, 2024
Marketing, Quality of life, Patient, Webcast, STIM, Telephone

The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Key Points: 
  • The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
  • The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7cha7jae.
  • To listen to the conference call on your telephone, participants may register for the call here .
  • While it is not required, it is recommended you join 10 minutes prior to the event start.

Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System

Retrieved on: 
Monday, February 12, 2024
Marketing, Quality of life, Patient, Transcranial magnetic stimulation, STIM, Health, Neuronetics, SVP

The update introduces features to streamline the way practices track and document status for their potential and current patients.

Key Points: 
  • The update introduces features to streamline the way practices track and document status for their potential and current patients.
  • "It's essential for healthcare providers to have the most recent technology that supports them in continuously improving patient care processes," stated Cory Anderson, SVP of R&D and Clinical.
  • All the features are designed to save practices time, allowing them to focus more on direct patient care rather than administrative tasks.
  • Another notable feature in this TrakStar release is a more robust Benefits Investigation report that provides practices with estimated patient financial responsibility prior to a patient beginning treatment.

NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update

Retrieved on: 
Tuesday, February 6, 2024
Policy, Health policy, Patient, Transcranial magnetic stimulation, Marketing, TMS, Depression, Quality of life, STIM, Insurance

The policy update reduces the number of antidepressant medication attempts from four down to two prior to TMS eligibility.

Key Points: 
  • The policy update reduces the number of antidepressant medication attempts from four down to two prior to TMS eligibility.
  • “I am pleased to witness the collective efforts leading to improved access to mental health coverage,” stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. “We commend Lucet Health for recognizing the importance of ensuring that individuals can access proven treatments like NeuroStar earlier in their path towards wellness.”
    Lucet Health is a behavioral health organization that works with large insurance carriers across the country.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy changes.
  • For more information about NeuroStar TMS Therapy, visit www.NeuroStar.com .

Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory

Retrieved on: 
Monday, December 18, 2023
Neuronetics, Marketing, Quality of life, Food, FDA, TMS, HSS, Mental health, SVP, Patient, STIM, Medical device

This proprietary accessory, designed with versatility and provider convenience in mind, seamlessly integrates with both legacy and new NeuroStar systems and further enhances efficiency and patient experience.

Key Points: 
  • This proprietary accessory, designed with versatility and provider convenience in mind, seamlessly integrates with both legacy and new NeuroStar systems and further enhances efficiency and patient experience.
  • “The NeuroSite™ FDA clearance is the latest of many enhancements designed to improve the patient experience, exemplifying our ongoing commitment to continually advance medical technology for mental health,” stated Cory Anderson, SVP of R&D and Clinical.
  • “We are thrilled to introduce yet another innovative accessory to our suite of products that deliver a fast, easy, reliable treatment that both patients and providers trust.”
    By leveraging the patient's unique anatomical features, NeuroSite™ Coil Placement Accessory ensures precise and reproducible coil placement.
  • “This latest tool reinforces my confidence in providing consistent results and truly exceptional care to my patients.”
    NeuroSite™ will be available to all NeuroStar providers beginning in Q1 of 2024.

NeuroStar TMS Receives Expanded Regulatory Approval in Japan

Retrieved on: 
Monday, December 4, 2023
Neuronetics, Marketing, Quality of life, Partnership, Depression, Medication, TMS, MDSAP, DSM-IV codes, Health, MDD, Patient, Transcranial magnetic stimulation, STIM, Dash, PMDA

The features covered in this approval include the NeuroStar 3.7 platform, MT Cap , D-Tect ™ MT Accessory, and the Dash treatment protocol.

Key Points: 
  • The features covered in this approval include the NeuroStar 3.7 platform, MT Cap , D-Tect ™ MT Accessory, and the Dash treatment protocol.
  • The Dash treatment protocol reduces the daily TMS treatment time from 38 minutes to under 19 minutes.
  • NeuroStar TMS Therapy aims to fill this unmet need through its exclusive distribution partnership with Teijin Pharma Limited.
  • NeuroStar is advancing its global strategy and strengthening its global presence with recent announcements of regulatory approval in South Korea , as well as EU-MDR and MDSAP certifications.

Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Wednesday, November 15, 2023
Marketing, Webcast, Quality of life, Patient, STIM, Conference, Pharmaceutical industry, Mail order

MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.

Key Points: 
  • MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.
  • The Company is scheduled to present at 2:00 pm Eastern Time the same day via webcast.
  • A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com .
  • A replay of the webcast will be archived on the website for approximately 90 days.

NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements

Retrieved on: 
Monday, November 13, 2023
Attention, TMS, Data management, Patient, STIM, Practice management, Marketing, Workflow, Software, Neuronetics, Mental health, Quality of life, Health, SVP, Nursing

“These updates represent our goal to support NeuroStar devices throughout their operational lifespan and build a foundation for future improvements.

Key Points: 
  • “These updates represent our goal to support NeuroStar devices throughout their operational lifespan and build a foundation for future improvements.
  • In addition to the NeuroStar software update, TrakStar’s software is upgraded to significantly enhance patient care and practice management.
  • These real-time notifications empower practices to swiftly identify patients who may require a follow-up NeuroStar treatment or clinical evaluation.
  • NeuroStar continually demonstrates that they are committed to best-in-class patient care and outcomes.”
    The NeuroStar software will be rolled out in phases during the 4th quarter, starting today.